80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]方主亭 唐 儀 吳少杰 周艷峰 楊厚林 陳良生 蔡森林 何劍鋒.經(jīng)頸靜脈肝內(nèi)門體分流術(shù)治療肝硬化頑固性腹水8例[J].福建醫(yī)藥雜志,2019,41(02):13-16.
　FANG Zhuting,TANG Yi,WU Shaojie,et al.Application of transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites[J].FUJIAN MEDICAL JOURNAL,2019,41(02):13-16.
點(diǎn)擊復(fù)制

經(jīng)頸靜脈肝內(nèi)門體分流術(shù)治療肝硬化頑固性腹水8例()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
41
期數(shù):
2019年02期
頁碼:
13-16
欄目:
臨床研究
出版日期:
2019-01-30

文章信息/Info

Title:
Application of transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites
文章編號(hào):
1002-2600(2019)02-0013-04
作者:
方主亭 唐 儀 吳少杰 周艷峰 楊厚林 陳良生 蔡森林 何劍鋒
福建醫(yī)科大學(xué)省立臨床醫(yī)學(xué)院 福建省立醫(yī)院介入放射科(福州 350001)
Author(s):
FANG Zhuting;  TANG Yi;  WU Shaojie;  ZHOU Yanfeng;  YANG Houlin;  CHEN Liangsheng;  CAI Senlin;  HE Jianfeng.
Department of Interventional Therapy, Fujian Provincial Hospital,Provincial Clinical Medical College of Fujian Medical University,Fuzhou 350001, China
關(guān)鍵詞:
經(jīng)頸靜脈肝內(nèi)門體分流術(shù);  肝硬化;  頑固性腹水
Keywords:
transjugular intrahepatic portosystemic shunt;  liver cirrhosis;  refractory ascites
分類號(hào):
R657.31
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 觀察采用經(jīng)頸靜脈肝內(nèi)門體分流術(shù)(transjugular intrahepatic portosystemic shunt,TIPS)治療肝硬化頑固性腹水患者的療效。方法 對(duì)8例肝硬化頑固性腹 水患者采用TIPS 治療,觀察其臨床療效,并對(duì)肝功能、血氨、凝血酶原時(shí)間及并發(fā)癥等指標(biāo)進(jìn) 行隨訪觀察。結(jié)果 對(duì)于肝硬化頑固性腹水的患者行TIPS治療后門靜脈壓力顯著下降,患者腹圍 顯著小于治療前,尿量顯著增加。顯效3例,有效4例。1例患者因穿刺后肝包膜出血,予行肝動(dòng)脈 栓塞后導(dǎo)致慢性肝功能衰竭而死亡。結(jié)論 TIPS治療肝硬化頑固性腹水療效確切。
Abstract:
Objective To observe the effects of the treatment of refractory ascites in cirrhotic patients using transjugular intrahepatic portosystemic shunt (TIPS). Methods The clinical effects of eight cirrhotic patients with refractory ascites who were treated by TIPS were observed. Then we conducted the follow-up and measured the liver function, renal function, blood routine, blood ammonia and complications of the patients. Results The portal venous pressure declined significantly after TIPS. The abdominal girth reduced significantly than before. The urine volume increased significantly than before. Three cases were markedly effective. Four cases were effective.One patient died because of chronic liver failure. Conclusion The effects of the treatment of refractory ascites in cirrhotic patients using TIPS are exact.

參考文獻(xiàn)/References:

[1] Planas R,Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol,2006,4(11):1385-1394.
[2] Krag A,Bendtsen F,Henriksen J H,et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J]. Gut,2010,59(1):105-110.
[3] 中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì). 肝硬化腹水及相關(guān)并發(fā)癥的診療指南[J]. 臨床肝膽病雜 志,2017,33(10):1847-1863.
[4] de Franchis R. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.
[5] Bureau C,Thabut D,Oberti F,et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites[J]. Gastroenterology,2017,152(1):157-163.
[6] Bucsics T,Hoffman S,Grunberger J,et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis[J]. Liver Int,2018,38(6):1036-1044.
[7] Geeroms B,Laleman W,Laenen A,et al. Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients:Long-term patency and clinical outcome results[J]. Eur Radiol,2017,27 (5):1795-1803.
[8] Ferral H,Gamboa P,Postoak D W,et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score[J]. Radiology,2004,231(1):231-236.
[9] Maleux G,Perez-Gutierrez N A,Evrard S,et al. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites:a retrospective cohort study[J]. Acta Gastroenterol Belg,2010,73(3):336-341.
[10] Miraglia R,Maruzzelli L,Tuzzolino F,et al. Transjugular Intrahepatic Portosystemic Shunts in Patients with Cirrhosis with Refractory Ascites: Comparison of Clinical Outcomes by Using 8- and 10-mm PTFE-covered Stents[J]. Radiology,2017,284(1):281-288.
[11] Wang Q,Lv Y,Chen H,et al. Use of 8-mm Covered TIPS:Is "Losses without Gains" the End of the Story?[J]. Radiology,2017,284(2):604.
[12] Gines P,Uriz J,Calahorra B,et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis[J]. Gastroenterology,2002,123(6):1839-1847.

相似文獻(xiàn)/References:

[1]陳玲玲 吳梅梅 林偉國(guó) 鄭偉兵 朱 琪.瞬時(shí)彈性成像技術(shù)在肝纖維化及脂肪肝診斷中的作用[J].福建醫(yī)藥雜志,2020,42(02):29.
　CHEN Lingling,WU Meimei,LIN Weiguo,et al.Role of Fibroscan in the diagnosis of liver fibrosis and hepatic steatosis[J].FUJIAN MEDICAL JOURNAL,2020,42(02):29.
[2]林雪燕,黃胡萍,林志輝.特利加壓素治療肝硬化食管胃靜脈曲張出血期間血鈉下降的影響因素分析[J].福建醫(yī)藥雜志,2022,44(03):26.

更新日期/Last Update: 2019-01-30